Back to Sectors

ATRC

AtriCure, Inc.
7 filings tracked
healthcaremedical devicesMID ($2B-10B)

Signal Magnitude Chart

BULLISH | 70% | 5/6/2026 | earnings beatBULLISH | 60% | 5/6/2026 | margin expansionBULLISH | 80% | 5/6/2026 | regulatory actionBEARISH | 50% | 5/6/2026 | margin compressionBULLISH | 70% | 5/6/2026 | earnings beatBULLISH | 60% | 5/6/2026 | margin expansionBULLISH | 80% | 5/6/2026 | regulatory actionBEARISH | 50% | 5/6/2026 | margin compressionBULLISH | 70% | 5/6/2026 | earnings beatBULLISH | 60% | 5/6/2026 | margin expansionBULLISH | 80% | 5/6/2026 | regulatory actionBEARISH | 50% | 5/6/2026 | margin compressionBULLISH | 70% | 5/6/2026 | earnings beatBULLISH | 60% | 5/6/2026 | margin expansionBULLISH | 80% | 5/6/2026 | regulatory actionBEARISH | 50% | 5/6/2026 | margin compressionBULLISH | 70% | 5/6/2026 | earnings beatBULLISH | 60% | 5/6/2026 | margin expansionBULLISH | 80% | 5/6/2026 | regulatory actionBEARISH | 50% | 5/6/2026 | margin compressionBULLISH | 70% | 5/6/2026 | earnings beatBULLISH | 60% | 5/6/2026 | margin expansionBULLISH | 80% | 5/6/2026 | regulatory actionBEARISH | 50% | 5/6/2026 | margin compressionBULLISH | 70% | 5/6/2026 | earnings beatBULLISH | 60% | 5/6/2026 | margin expansionBULLISH | 80% | 5/6/2026 | regulatory actionBEARISH | 50% | 5/6/2026 | margin compressionMay 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bullishMay 6

Swung from a net loss to a net profit of $108k in Q1 2026.

earnings beat
70%
bullishMay 6

Gross margin expanded 246 basis points to 77.4%.

margin expansion
60%
bullishMay 6

Received CE mark approval for FLEX-Mini and PRO-Mini devices in Europe.

regulatory action
80%
bearishMay 6

SG&A expenses remain high at 59.9% of total revenue.

margin compression
50%
bullishMay 6

Swung from a net loss to a net profit of $108k in Q1 2026.

earnings beat
70%
bullishMay 6

Gross margin expanded 246 basis points to 77.4%.

margin expansion
60%
bullishMay 6

Received CE mark approval for FLEX-Mini and PRO-Mini devices in Europe.

regulatory action
80%
bearishMay 6

SG&A expenses remain high at 59.9% of total revenue.

margin compression
50%
bullishMay 6

Swung from a net loss to a net profit of $108k in Q1 2026.

earnings beat
70%
bullishMay 6

Gross margin expanded 246 basis points to 77.4%.

margin expansion
60%
bullishMay 6

Received CE mark approval for FLEX-Mini and PRO-Mini devices in Europe.

regulatory action
80%
bearishMay 6

SG&A expenses remain high at 59.9% of total revenue.

margin compression
50%
bullishMay 6

Swung from a net loss to a net profit of $108k in Q1 2026.

earnings beat
70%
bullishMay 6

Gross margin expanded 246 basis points to 77.4%.

margin expansion
60%
bullishMay 6

Received CE mark approval for FLEX-Mini and PRO-Mini devices in Europe.

regulatory action
80%
bearishMay 6

SG&A expenses remain high at 59.9% of total revenue.

margin compression
50%
bullishMay 6

Swung from a net loss to a net profit of $108k in Q1 2026.

earnings beat
70%
bullishMay 6

Gross margin expanded 246 basis points to 77.4%.

margin expansion
60%
bullishMay 6

Received CE mark approval for FLEX-Mini and PRO-Mini devices in Europe.

regulatory action
80%
bearishMay 6

SG&A expenses remain high at 59.9% of total revenue.

margin compression
50%
bullishMay 6

Swung from a net loss to a net profit of $108k in Q1 2026.

earnings beat
70%
bullishMay 6

Gross margin expanded 246 basis points to 77.4%.

margin expansion
60%
bullishMay 6

Received CE mark approval for FLEX-Mini and PRO-Mini devices in Europe.

regulatory action
80%
bearishMay 6

SG&A expenses remain high at 59.9% of total revenue.

margin compression
50%
bullishMay 6

Swung from a net loss to a net profit of $108k in Q1 2026.

earnings beat
70%
bullishMay 6

Gross margin expanded 246 basis points to 77.4%.

margin expansion
60%
bullishMay 6

Received CE mark approval for FLEX-Mini and PRO-Mini devices in Europe.

regulatory action
80%
bearishMay 6

SG&A expenses remain high at 59.9% of total revenue.

margin compression
50%

Filing History

10-QMay 6, 2026

The Q1 2026 filing reveals a company at a crossroads between scaling its operational efficiency and fighting structural market shifts. While the swing to net profitability and the growth in pain management are strong positive signals, the stark decline in minimally invasive ablation highlights the disruptive impact of PFA technology. The company's ability to maintain its 77.4% gross margin while aggressively scaling its international presence will be the primary driver of shareholder value. Ultimately, the investment thesis hinges on whether the imminent European launch and the long-term LeAAPS trial data can offset the high fixed costs of the SG&A base. Investors are weighing a fortress-like cash position of $146 million against a business model that is still refining its path to sustainable, scalable cash flow.